Salesforce (CRM) Added to Analyst Current Favorite at Raymond James

Get Alerts CRM Hot Sheet
Rating Summary:
45 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 16
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Salesforce (NYSE: CRM) shares were named Raymond James' Analyst Brian Peterson's Current Favorite, with the firm writing that the software company "could be at an inflection point," in a note Monday.
In the note, Raymond James said it is surprised by recent underperformance in CRM stock, "particularly given its ability to hold margin guidance steady (despite a lower top-line outlook) and a ~$10 billion share repurchase authorization."
The comments come ahead of CRM's analyst day and user conference this week "with messaging likely confirming a healthy durable growth profile and getting more comfort on margins/dilution," the event could offer a positive catalyst for the stock, said Peterson.
The analyst, who has a Strong Buy rating on CRM, declared: "We like that risk/reward, and we're making shares our new Analyst Current Favorite."
Elsewhere, Jefferies analyst Brent Thill, who has a Buy rating and $250 price target on CRM shares, told investors in a note that they expect CRM to provide innovation updates (Slack integration), update F26 top line goals (Street at $48B vs. prior goal of $50B), and give higher margins at its investor day.
"While we do not expect a F24 top line guide, we do expect comments on margins (Street at 21.6% vs. F23E at 20.4%). We also expect a F26 margin target (Street at 25%) and a share buyback timeline ($10B announced). CRM trades close to trough levels at 4x' 23E rev," Thill stated.
By Sam Boughedda
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Petrobras (PBR) has 'further room for capital appreciation' - Morgan Stanley
- Apple (AAPL) Pay 'outgrowing Google Pay and Samsung Pay in recent years' - Barclays
- Exact Sciences (EXAS) PT Raised to $100 at Jefferies; 'incrementally positive' following meetings
Create E-mail Alert Related Categories
Analyst Comments, Hot ListRelated Entities
Raymond James, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!